Report Description of the EU Short Bowel Syndrome Market Analysis
Research Scope and Assumption
- The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
- The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
- We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
- All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
- Inflation has not been accounted for in order to estimate and forecast the market
- Numbers may not add up due to rounding off
Reason to buy the report:
- Facilitate decision-making based on strong current and forecast data for EU Short Bowel Syndrome Market Analysis
- Develop strategies based on the latest regulatory framework
- Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
- Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the EU Short Bowel Syndrome Market Analysis
- Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
- To strategically profile key players and comprehensively analyze their market shares and core competencies
- We have technically sound team which do a deep dive research and also provide strategy based consulting analysis
EU Short Bowel Syndrome Market Analysis Executive Summary
Short bowel syndrome is a group of complex diseases that occurs due to malfunction of a portion of small and/or large intestine. The individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other vital elements which leads to malnutrition, weight loss. However, in some cases, short bowel syndrome can lead to severe, disabling and life-threatening complications. There is no particular cure to this disorder however surgical removal (resection) of half or more of the small intestine is effective. Short bowel syndrome can lead to Crohn’s disease, injury or trauma to the small intestine. Such complications are making a significant contribution to the growth of the short bowel syndrome market.
Market Size and Key Findings
The EU Short Bowel Syndrome Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Market Dynamics
Market Growth Drivers Analysis
With the rise in demand of various drugs, there are various drugs in clinical development pipeline consists of several first-in-class drugs that are effective and safe for short bowel syndrome patients. And as these drugs gets launched, Strong pipeline drugs for short bowel syndrome they can act as a key driver of the market. The factors such as increasing investments made on UHT (Ultra Heat Treatment) treatment for other products, increasing production capacities of UHT treatment plants are amongst the major factor projected to impel growth of Short Bowel Syndrome Market
Market Restraints
The cost of treatment of rare diseases is significantly high, which makes the treatment unaffordable for low-income groups. Additionally, lack of reimbursement in certain countries renders the treatment unreachable to several target group people.
Competitive Landscape
Key Players
The global short bowel syndrome market is moderately competitive and consists of several prominent industry players. Some prominent players are making partnerships and acquiring the blockbuster products in the market, other companies and expanding their market position globally. For instance, Takeda acquired the Shire, to expanding its geographic footprint and to be a leader in providing targeted treatments in gastroenterology, the leading companies in gastroenterology (GI) and neuroscience. While other key players are focusing on distributing and manufacturing of over-the-counter dietary supplements. Whereas, some companies such as Naia Pharmaceuticals SBS, Micelle BioPharma, Inc. are having new products in their pipeline. Some of the companies which are currently dominating the market are TAKEDA Inc, Naia Pharmaceuticals Inc, VectivBio AG, OxThera Inc, and Nutrinia Inc.
Products in Pipeline
Takeda Pharmaceuticals, on May 2019, announced that the US FDA approved extending the indication of GATTEX (teduglutide) for injection to pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding (parenteral support).
Notable Recent Deals
- On April 30 2020, 9 Meters Biopharma, Inc. completed merger with privately held RDD Pharma, Ltd., an Israel-based corporation (“RDD”) (the “RDD Merger”) and changed its name from Innovate Biopharmaceuticals, Inc. to 9 Meters Biopharma, Inc.
- On January 2019, Takeda Pharmaceutical Company Limited completed the acquisition of Shire plc., becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Post the acquisition, Takeda has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly innovative medicines to around 80 countries/regions with dedicated employees across the world.
Healthcare Policies and Regulatory Landscape
Policy changes and Reimbursement scenario
Intestinal Tissue Engineering Solution-
Short Bowel Syndrome (SBS) is a condition that occurs when part or the entire small intestine is missing or has been removed during surgery. This condition renders the bowel incapable of fulfilling its nutritional function (intestinal failure). There is no cure for SBS. Parenteral (intravenous) nutrition (PN) and bowel transplantation are currently the preferred options for nutrition in children and adults who have lost their bowel. PN offers a low survival rate, compromised quality of life, and the economic cost for each patient is estimated to be 55,000 euro/year. Small intestinal transplant is also an option with one-year and 4-year survival rates of 90% and 60% respectively. However, because of the shortage of organs, high mortality, the severe side effects of immunosuppression and low quality of life, this is still a sub-optimal solution.
The objective of this programme is to deliver a functional bowel reconstruction to patients with SBS through an autologous tissue engineering strategy, overcoming the shortage of organs, and avoiding the need for immunosuppression. It will be achieved by identifying the best autologous cell source; providing the ideal scaffold; engineering functional intestine for transplantation and engaging with patients, scientists and public. The work is designed to lead directly to a clinical trial for the application of the optimal protocol for tissue-engineered intestine. The consortium is uniquely positioned to complete this ambitious effort as we have an internationally pre-eminent, multi-disciplinary team, which possesses a combination of expertise from basic molecular biology, engineering, and surgery, combining knowledge from universities, hospitals and industry. Importantly we are one of the few groups in the world with experience, infrastructure, and track record to translate regenerative medicine solutions to patients, including true clinical translation of tissue engineered organs.